Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis’ new heart failure medicine recommended for EU approval

September 25, 2015
Medical Communications, Research and Development Entresto, Novartis, eams, heart failure

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Novartis’s heart failure medication Entresto …

News
velocity_health

Merck and Wayra to tackle NHS funding gap with startup rewards programme

September 25, 2015
Research and Development MSD, Merck

Merck Sharpe and Dohme (MSD) and Wayra Open Future, Telefonica’s digital start up accelerator, are investing in digital innovation in …

News
abpi_acting_ceo_alison_clough

ABPI responds to UK medicines cost controversy

September 25, 2015
Medical Communications, Sales and Marketing ABPI, Cancer Drugs Fund, NHS

Alison Clough, acting CEO of the Association of the British Pharmaceutical Industry (ABPI), has responded to recent reports in the …

News
copd

Genetic study reveals new associations with lung disease and smoking behaviour

September 25, 2015
Medical Communications, Research and Development COPD, lung cancer, smkoing

New research published in The Lancet Respiratory Medicine and presented at this year’s European Respiratory Society (ERS) Congress in Amsterdam …

News
novartis_access_ncds_facts

Novartis launches affordable medicines portfolio for lower-income countries

September 24, 2015
Manufacturing and Production, Sales and Marketing Novartis

Novartis has announced the launch of ‘Novartis Access’, a portfolio of 15 medicines to treat chronic diseases in low and …

News
gilead-sciences

NICE approves first in new class of leukaemia drugs

September 24, 2015
Cancer Drugs Fund, Gilead Sciences, NHS, NICE, idelalisib, leukaemia, zydelig

NICE has issued final draft guidance which recommends that Gilead’s Zydelig should be made available on the NHS for some …

News
turing_pharma

Turing will drop price of Daraprim following outrage

September 24, 2015
Sales and Marketing Daraprim, Impax Laboratories, Martin Shkreli, Turing Pharmaceuticals, toxoplasmosis

Martin Shkreli, whose company Turing Pharmaceuticals increased the price of Daraprim more than fifty-fold overnight, has been forced to backpedal …

News
BI building

Boehringer and BioMed X crowdsource top scientists to fight COPD

September 23, 2015
Research and Development Boehringer Ingelheim, COPD

Boehringer Ingelheim and BioMed X have used a crowdsourcing strategy to establish a global research team to collaborate on the …

News
HIV infected cell

ViiV in late-stage HIV trial success

September 23, 2015
Research and Development HIV, Triumeq, ViiV, virology

Switching patients to Triumeq, a once-daily combination treatment for HIV, is as effective as remaining on antiretroviral therapy in certain …

News

Pharma ‘is getting better at drug R&D’

September 23, 2015
Research and Development R&D, drug development, market access, productivity

An investigation into pharma R&D data shows that drugmakers are becoming more successful at identifying the right candidates for drug …

News
nn_flag

Novo Nordisk to build manufacturing plant for FlexPen in Iran

September 22, 2015
Manufacturing and Production Iran, Novo Nordisk, diabetes

Novo Nordisk has announced that Novo Nordisk Iran and the Food and Drug Administration of the Islamic Republic of Iran …

News
martin_shkreli

Anger as drug price rises from $13.50 to $750 overnight

September 22, 2015
Manufacturing and Production, Sales and Marketing pyrimethamine, turing

Turing founder Martin Shkreli has been forced to defend the company’s decision to raise the price of the drug Daraprim …

News
scottish_highlands

Vision for hi-tech manufacturing in the Scottish highlands

September 22, 2015
Manufacturing and Production, Research and Development GSK, Scotland, manufacturing

Scottish life and chemical science firms claim Scotland is an ideal European base for UK and global manufacturers. A new …

News
Zoloft

Pfizer and GSK in antidepressant safety probes

September 22, 2015
Manufacturing and Production GSK, Paxil, Pfizer, Zoloft, antidepressants, drug safety, paroxetine, sertraline

Two top-selling antidepressants have had their safety records challenges, after the FDA asked Pfizer to change the labelling of its …

News

Featured market report: Cancer diagnostics market – Forecast to 2020

September 22, 2015
Manufacturing and Production, Sales and Marketing cancer diagnostics, market report, marketsandmarkets

The global cancer diagnostics market is witnessing a rapid transformation owing to several technological advancements in diagnostic platforms.Moreover, the market …

Feature
Shire

Shire ADHD treatment Intuniv gets EU approval

September 21, 2015
Sales and Marketing ADHD, Shire, attention deficit hyperactivity disorder, intuniv

The European Commission has granted marketing authorisation for Shire’s Intuniv for the treatment of ADHD in children.  Intuniv (guanfacine hydrochloride prolonged …

News
Klaus Henning Jensen

Working Life: Novo Nordisk’s Klaus Henning-Jensen

September 21, 2015
Sales and Marketing Novo Nordisk, Working Life

How did you find your way into your current role?I started out in medicine at Bispebjerg, which is a large …

Feature
Amgen image

Amgen’s Kyprolis gets accelerated FDA review for expanded labelling

September 21, 2015
Sales and Marketing Amgen, FDA, Kyprolis, carfilzomib, multiple myeloma

The FDA has accepted for priority review Amgen’s supplemental new drug application for Kyprolis (carfilzomib) for patients with relapsed multiple …

News
Esbriet

Roche to present new Esbriet data at ERS Congress 2015

September 21, 2015
Research and Development, Sales and Marketing Esbriet, European Respiratory Congress, Roche, idiopathic pulmonary fibrosis, pirfenidone

Roche has announced it will present new data analyses of Esbriet in idiopathic pulmonary fibrosis (IPF) at the European Respiratory …

News
Jardiance

More positive CV data for Boehringer and Lilly’s Jardiance

September 21, 2015
Research and Development, Sales and Marketing Boehringer Ingelheim, EASD, Eli Lilly, cardiovascular risk, empagliflozin, jardiance, mortality risk, type 2 diabetes

Jardiance, an anti-diabetes drug produced by Boehringer Ingelheim and Eli Lilly, reduces the risk of death in people with type …

News
The Gateway to Local Adoption Series

Latest content

Campaign highlights low expectations among patients with depression

May 7, 2026

Practical AI toolkit launched to help manufacturers cut through complexity

May 6, 2026

Syngene appoints Maninder Kapoor Puri as CHRO

May 6, 2026

BioPhorum acquires PharmaX Solutions

May 5, 2026

Syngene appoints Abhijit Zutshi as CCO

May 5, 2026